ArticleOcular oncology and pathology2026
Minimally Invasive Iris Melanoma Resection and Cataract Surgery.
Article in Ocular oncology and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study was to compare the outcomes of minimally invasive iris melanoma resection (MIMR) with or without combined cataract surgery (CS) in patients with circumscribed iris melanoma, with the goal of developing evidence-based guidance for surgical management. Methods: This retrospective, multicenter case series included 89 patients treated at Copenhagen University Hospital (Denmark) and Cole Eye Institute, Cleveland Clinic (USA). Danish patients underwent combined MIMR and CS with iris diaphragm, while US patients underwent MIMR only. Outcomes included visual acuity, anterior chamber stability, induced astigmatism, cataract progression, and surgical complications. Tumor-related outcomes were tumor size, local recurrence, and development of metastasis. Statistical analyses were performed using R, with Results: Median age and follow-up differed between cohorts: 76 years and 13 months (range, 12-38) in the Danish cohort, compared with 58 years and 47 months (range, 1-145) in the American cohort ( Conclusions: Both standalone and combined MIMR demonstrated excellent safety, with low complication rates (<5%). No metastatic events were observed, and tumor recurrence occurred in only 3.4% of cases. In the combined MIMR + CS cohort, early visual recovery was superior, whereas standalone MIMR preserved lens status and induced minimal astigmatic change. These outcomes reflect distinct patient profiles - older cataractous versus younger phakic eyes - highlighting the importance of individualized surgical planning. Given its strong local control and low systemic risk, MIMR represents a safe and effective surgical option for localized iris melanoma, with combined procedures preferred when cataract coexists or is expected to progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.